Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Join Barchart Premier to attend LIVE "Market on Close" program each Friday with John Rowland. FREE 30 Day Trial
Stocks | Futures | Watchlist | More
or

Verve Therapeutics Inc (VERV)

Verve Therapeutics Inc (VERV)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Profile for [[ item.sessionDateDisplayLong ]]

Company Info

Verve Therapeutics Inc 201 BROOKLINE AVENUE SUITE 601 BOSTON MA 02215 USA

www.vervetx.com P: 617-603-0070

Description:

Verve Therapeutics is a genetic medicines company pioneering a new approach to the care of cardiovascular disease, transforming treatment from chronic management to single-course gene editing medicines. The company's lead product candidate includes VERVE-101. Verve Therapeutics is based in CAMBRIDGE, Mass.

Key Statistics

Overview:

Market Capitalization, $K 537,946
Enterprise Value, $K 331,766
Shares Outstanding, K 83,923
Annual Sales, $ 11,760 K
Annual Net Income, $ -200,070 K
Last Quarter Sales, $ 5,140 K
Last Quarter Net Income, $ -48,350 K
EBIT, $ -223,120 K
EBITDA, $ -232,050 K
60-Month Beta 1.94
% of Insider Shareholders 21.40%
% of Institutional Shareholders 97.11%
Float, K 65,963
% Float 78.60%
Short Volume Ratio 0.47

Growth:

1-Year Return -60.31%
3-Year Return 0.00%
5-Year Return 0.00%
5-Year Revenue Growth 0.00%
5-Year Earnings Growth 0.00%
5-Year Dividend Growth 0.00%

Per-Share Information:

Most Recent Earnings -0.69 on 02/27/24
Latest Earnings Date 05/20/24
Earnings Per Share ttm -3.12
EPS Growth vs. Prev Qtr 4.17%
EPS Growth vs. Prev Year -2.99%
Annual Dividend Yield 0.00%
Dividend Payout Ratio 0.00%

VERV Ratios

Ratio
Price/Earnings ttm 0.00
Price/Earnings forward N/A
Price/Earnings to Growth N/A
Return-on-Equity % -39.33%
Return-on-Assets % -30.92%
Profit Margin % -1,701.28%
Debt/Equity 0.00
Price/Sales 43.90
Price/Cash Flow N/A
Price/Book 0.82
Book Value/Share 7.31
Interest Coverage -3.00
Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.

Free Barchart Webinar